Aligos Therapeutics (ALGS) announced that the United States Adopted Names, USAN, Council has adopted pevifoscorvir sodium as the nonproprietary name for ALG-000184, under investigation for the treatment of chronic hepatitis B virus, HBV, infection. The USAN, consisting of members from the Food and Drug Administration, FDA, American Medical Association, AMA, United States Pharmacopeia, USP, and the American Pharmacists Association, APhA, is responsible for developing simple, informative nonproprietary drug names.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
- Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target
- Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs
- Aligos Therapeutics: Promising Advancements in HBV Treatment and Strategic Pipeline Growth
- Aligos Therapeutics assumed with a Buy at H.C. Wainwright